| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:LY2140023
CAS:635318-55-7
Purity:98% Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
| Products Intro: |
Product Name:LY2140023
CAS:635318-55-7
Purity:99% HPLC Package:50Mg,100Mg,500Mg,1g,5g,10g,50g,100g,500g,1kg Remarks:XYA0456
|
| Company Name: |
LETOPHARM LIMITED
|
| Tel: |
+86-21-5821 5861 |
| Email: |
sales@letopharm.com |
| Products Intro: |
Product Name:LY2140023
CAS:635318-55-7
|
| Company Name: |
Chunchuang (Wuhan) Technology Co., Ltd
|
| Tel: |
15727060112 |
| Email: |
yutianchun2007@126.com |
| Products Intro: |
Product Name:LY 2140023
CAS:635318-55-7
Purity:97%~99% HPLC Package:1mg;1g;10g;100g;1Kg;10Kg;100Kg;1T
|
|
| | LY 2140023 Basic information |
| Product Name: | LY 2140023 | | Synonyms: | VOYCNOJFAJAILW-CAMHOICYSA-N;LY2140023 monohydrate;2-Thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid, 4-[[(2S)-2-amino-4-(methylthio)-1-oxobutyl]amino]-, 2,2-dioxide, (1R,4S,5S,6S)-;Pomaglumetad methionil anhydrous;PoMagluMetad Methionil | | CAS: | 635318-55-7 | | MF: | C12H18N2O7S2 | | MW: | 366.41 | | EINECS: | | | Product Categories: | | | Mol File: | 635318-55-7.mol |  |
| | LY 2140023 Chemical Properties |
| Melting point | 203 °C | | Boiling point | 773.6±60.0 °C(Predicted) | | density | 1+-.0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMSO: 0.25mg/mL
dilute NaOH: 10mg/mL | | pka | 2.14±0.40(Predicted) | | form | powder | | color | white | | InChI | 1S/C12H18N2O7S2/c1-22-3-2-5(13)9(15)14-12(11(18)19)4-23(20,21)8-6(7(8)12)10(16)17/h5-8H,2-4,13H2,1H3,(H,14,15)(H,16,17)(H,18,19)/t5-,6+,7+,8-,12+/m0/s1 | | InChIKey | VOYCNOJFAJAILW-OZFRBSTCSA-N |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | LY 2140023 Usage And Synthesis |
| Uses | LY 2140023 is a drug developed as a treatment option for schizophrenia. It targets the mGlu2/3 receptor once metabolized. | | Biological Activity | Primary Target
mGlu2 & mGlu3', 'Target Ki: 149 nM and 92 nM for human mGlu2 and mGlu3, respectively. | | in vivo | Pomaglumetad methionil (LY2140023; orally; 3-300 mg/kg; once daily for 7 days) dose-dependent increases the levels of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)[1]. | Animal Model: | Male Fischer rats (approximately 250 g)[1] | | Dosage: | 3, 10, and 300 mg/kg | | Administration: | Orally; once daily for 7 days | | Result: | Dose-dependent increased the levels of the dopamine metabolites DOPAC and HVA.
|
| | IC 50 | mGluR2; mGluR3 |
| | LY 2140023 Preparation Products And Raw materials |
|